title: Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting.
abstract: Quality of life is impaired in patients with epilepsy and can be improved by effective therapy. Randomised clinical trials have shown that lamotrigine treatment is associated with improved quality of life. However, little information is available on quality of life or treatment effects in patients with epilepsy in the general population. The objective of this study was to estimate the impact of lamotrigine on quality of life in a naturalistic treatment setting. The study included adult patients with epilepsy in whom lamotrigine therapy was initiated. Each subject completed the Quality of Life in Epilepsy Inventory (QOLIE)-31 quality of life questionnaire at inclusion and at a follow-up visit in the next 4 months. Demographic information and medical history were provided by the investigator. These were evaluated as potential determinants of change in quality of life using logistic regression. Three hundred and forty-one patients were evaluated, 192 starting lamotrigine in combination with another drug, 90 as a first-line monotherapy, 45 as a switch from another drug and 14 as a reduction to monotherapy from a previous combination. Baseline scores on the QOLIE-31 ranged from 53.8 in the combination group to 69.5 in the first-line group. 34.6% of patients were considered to be responders, with no significant differences between treatment regimen. Most improvement was seen for the energy-fatigue and medication effects subscales and, for the first-line group, seizure worry. Seizure type was the only determinant of improvement of quality of life identified. In conclusion, lamotrigine treatment is associated with improved quality of life, regardless of treatment regimen.
authors.affiliation: Hôpital de Pontchaillou, Rennes, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Allain
authors.forename: Stéphane
authors.initials: S
authors.lastname: Schück
authors.forename: Fatima
authors.initials: F
authors.lastname: Nachit-Ouinekh
authors.forename: Perrine
authors.initials: P
authors.lastname: Plouin
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Brunon
authors.forename: Jacques
authors.initials: J
authors.lastname: Boulliat
authors.forename: Florence
authors.initials: F
authors.lastname: Mercier
authors.forename: Alain
authors.initials: A
authors.lastname: Slama
authors.forename: Michel
authors.initials: M
authors.lastname: Baulac
authors.forename: Abdelkader
authors.initials: A
authors.lastname: El Hasnaoui
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D019370:Observation; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014227:Triazines / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine